- Casa
- kit lamine sci
- Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy: Molecular Therapy - Oncolytics
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy: Molecular Therapy - Oncolytics
4.7 (440) · € 19.00 · In Magazzino
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte -based adoptive T cell therapy: Molecular Therapy - Oncolytics
CAR-T Cells Targeting Immune Checkpoint Pathway Players
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte -based adoptive T cell therapy: Molecular Therapy - Oncolytics
Cells, Free Full-Text
Delivery technologies for T cell gene editing: Applications in cancer immunotherapy - ScienceDirect
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte -based adoptive T cell therapy: Molecular Therapy - Oncolytics
Frontiers CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More
PD-1 gene editing by sgRNA/Cas9 RNP assembly in primary human T cells.
Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
Genome Editing in Engineered T Cells for Cancer Immunotherapy
Cancers, Free Full-Text
